CSNK1A1 and lymphoid neoplasm: CK1α degradation by FPFT-2216 was observed in vitro regardless of sensitivity to growth inhibition; FPFT-2216 did not exhibit growth inhibition against all p53 wild-type lymphoid tumor cells.